Subscribe
Share
Share
Embed
This video can be seen at: https://www.piworld.co.uk/2018/12/14/shield-therapeutics-stx-presentation-at-mello-london-november-2018/
Shield Therapeutics (STX) presentation at Mello London 2018By Tim Watts, CFO
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialisation of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anaemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.
Introduction – 00:17Iron deficiency and Feraccru – 01:56Norgine licence headlines – 11:28USA – 14:00Financial – 15:15Management team – 15:47Anticipated news flow – 17:00Key messages and investment highlights – 18:12
Shield Therapeutics (STX) presentation at Mello London 2018
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialisation of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anaemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.
Introduction – 00:17
Iron deficiency and Feraccru – 01:56
Norgine licence headlines – 11:28
USA – 14:00
Financial – 15:15
Management team – 15:47
Anticipated news flow – 17:00
Key messages and investment highlights – 18:12
Content for investors by investors . These are audio podcast versions of our videos. Sometimes slides are referred to, to view as videos go to www.piworld.co.uk